28 / 10 / 2025 TUE
Nile Pharmaceuticals (NIPH)
✓ Financial Period Ending 09/2025 (3M)
Revenue: EGP 681 million
Net Profit: EGP 106 million
Earnings per Share: EGP 3.53
✓ Financial Period Ending 09/2024 (3M)
Revenue: EGP 121 million
Net Loss: -EGP 11 million
Loss per Share: EGP 0.36
27 / 10 / 2025 MON
Arab Company for Pharmaceuticals and Chemical Industries (ADCI)
☑️ Decided to distribute a coupon of EGP 8.333 per share, effective October 30, 2025.
☑️ The right to receive the dividend will be transferred to the buyer until Monday, October 27, 2025.
26 / 10 / 2025 SUN
Alexandria Pharmaceuticals (AXPH)
✓ Financial period ending September 30, 2025
Revenues: EGP 799 million
Net profit: EGP 137 million
Earnings per share: EGP 27.4
✓ Financial period ending September 30, 2024
Revenues: EGP 768 million
Net profit: EGP 129 million
Earnings per share: EGP 25.8
15 / 10 / 2025 WED
Nile Pharmaceuticals (NIPH)
☑️ The company has decided to distribute a coupon of EGP 2 per share, effective November 2, 2025.
☑️ The right to receive the dividend will be transferred to share holders until the end of the trading session on Tuesday, October 28, 2025.
12 / 10 / 2025 SUN
Macro Group for Pharmaceuticals (MCRO)
Authorized capital increased from EGP 575 million to EGP 3 billion.
Issued capital increased from EGP 114 million to EGP 684.2 million, an increase of EGP 570.2 million. This increase will be financed in cash by inviting existing shareholders to subscribe at the nominal value of the share (EGP 0.20).
The subscription rights will be traded separately from the original share according to dates determined by the Board of Directors, subject to regulatory approval.
Approval of a services contract between Macro Group and Unimac International Group to exchange manufacturing services between the two companies.
25 / 9 / 2025 THU
| Premium Healthcare
Financial Regulatory Authority decides to continue suspension of Premium Healthcare shares and threatens to delist them
The Financial Regulatory Authority has decided to continue the suspension of trading in Premium Healthcare shares until the end of the trading session on September 28, 2025. This decision follows the company’s failure to allow the appointed auditor to review its cash flow statement and capital increase documents, as the company’s premises were found to be lacking the required documentation.
The Authority explained that the company’s board of directors moved the company’s headquarters to Port Said and approved a memorandum of understanding to acquire “Al-Israa Lab” in Upper Egypt, paying an initial installment of 15 million Egyptian pounds.
The Authority emphasized that if the company fails to comply with the requirement to allow the auditor access to the necessary documents, its shares will be delisted and placed on List D starting from the trading session on September 29, or upon issuance of a negative report from the auditor. The Authority warned investors of the potential risks involved.
21 / 9 / 2025 SUNDAY
Ibn Sina Pharma ISPH
☑️ The company has decided to distribute a coupon of EGP 0.16 per share, effective October 15, 2025.
☑️ The right to receive the dividend will be transferred to share holders until the end of the session on Sunday, October 12, 2025.
14 / 9 / 2025 SUNDAY
Ibnsina Pharma
Ibnsina Pharma maintains its leadership in the Egyptian pharmaceutical distribution market for the third consecutive year, with a market share of 31.1% during the first half of 2025, according to IQVIA reports.
Ibnsina Pharma announced that it has maintained its leadership in the pharmaceutical distribution market in Egypt for the third consecutive year, with a market share of 31.1% during the first half of 2025, according to IQVIA reports. It also led the pharmacies and warehouses sector with a 35% share, and the hospitals sector with a 22.3% share, confirming its market leadership. The company recorded a 54.8% growth in revenues, reaching EGP 35 billion, compared to EGP 22.8 billion in the same period of 2024.
Macro Group Pharmaceuticals
Macro Group Pharmaceuticals invites its shareholders to attend the Extraordinary General Assembly on October 8, 2025, to consider:
Increasing the authorized capital from EGP 575 million to EGP 3 billion, with amendments to Article (1) of the Articles of Association.
Increasing the issued capital from EGP 114.04 million to EGP 684.25 million, an increase of EGP 570.2 million, financed in cash by inviting existing shareholders to subscribe.
Issuing 2.85 billion new shares at a par value of EGP 0.20 per share, with the right to trade separately from the original share, if possible, and the full value to be paid upon subscription.
Amending the amount of additional shares to be issued as deemed appropriate by the Assembly
9 / 9 / 2025 TUE
Nile Pharmaceuticals (NIPH)
Reminder: The expiration date for the subscription rights, separate from the stock, is at the end of the trading session on Tuesday, September 9, 2025 (end of the rights trading period).
8 / 9 / 2025 MON
Memphis Pharmaceuticals (MPCI)
✓ Financial period ending June 30, 2025 (12M)
Revenues: EGP 1.50 billion
Net profit: EGP 0.50 billion
Earnings per share: EGP 22
P/E ratio: 7.6x
✓ Financial period ending June 30, 2024 (12M)
Revenues: EGP 0.87 billion
Net profit: EGP 0.19 billion
Earnings per share: EGP 8.4
7 / 9 / 2025 SUN
Alexandria Pharmaceuticals (AXPH)
Alexandria Pharmaceuticals and Chemical Industries has proposed a cash dividend of EGP 30 per share.
Totaling EGP 150 million, the dividend will be funded from the profits of the previous fiscal year.
31 / 8 / 2025 SUN
Arab Company for Pharmaceuticals and Chemical Industries (ADCI)
✓ Financial period ending June 30, 2025 (12M)
Revenue: EGP 1.1 billion
Net profit: EGP 227 million
Earnings per share: EGP 16.87
P/E ratio: 9.9x
✓ Financial period ending June 30, 2024 (12M)
Revenue: EGP 784 million
Net profit: EGP 102 million
Earnings per share: EGP 14.72
Cleopatra Hospital Company (CLHO)
✓ Financial period ending June 30, 2025 (6M)
Revenue: EGP 3.3 billion
Net profit: EGP 521 million
Earnings per share: EGP 0.31
✓ Financial period ending June 30, 2024 (6M)
Revenue: EGP 2.3 billion
Net profit: EGP 366 million
Earnings per share: EGP 0.23
12 / 8 / 2025 TUE
Nozha International Hospital (NINH)
✓ Financial period ending June 30, 2025 (6M)
Revenues: EGP 257 million
Net profit: EGP 81 million
Earnings per share: EGP 0.32
✓ Financial period ending June 30, 2024 (6M)
Revenues: EGP 202 million
Net profit: EGP 52 million
Earnings per share: EGP 0.20
10 / 8 / 2025 SUN
MEPA Medical Packaging
✓ Financial period ending June 30, 2025 (6M)
Revenues: EGP 65 million
Net profit: EGP 23 million
Earnings per share: EGP 0.035
✓ Financial period ending June 30, 2024 (6M)
Revenues: EGP 62 million
Net profit: EGP 22 million
Earnings per share: EGP 0.035
31 / 7 / 2025 THU
Arab Company for Pharmaceuticals and Chemical Industries (ADCI)
✓ Financial period ending June 30, 2025
Revenues: EGP 1.1 billion
Net profit: EGP 223 million
Earnings per share: EGP 16.24
P/E ratio: 7.9x
✓ Financial period ending June 30, 2024
Revenues: EGP 785 million
Net profit: EGP 102 million
Earnings per share: EGP 14.72
29 / 7 / 2025 TUE
Memphis Pharmaceuticals and Chemical Industries (MPCI)
Announces its unaudited financial results
✓ Fiscal year ending June 30, 2025
Revenues: EGP 1.5 billion
Net profit: EGP 504.9 million
Earnings per share: EGP 23.7
P/E ratio: 3.8x
✓ Fiscal year ending June 30, 2024
Revenues: EGP 871.9 million
Net profit: EGP 191.4 million
Earnings per share: EGP 14.5
7 / 7 / 2025 Mon
Rameda RMDA
The dividend distribution of EGP 0.106 per share will be distributed in two installments.
✓ The first installment, EGP 0.053, will be paid starting July 10, 2025.
✓ The second installment, EGP 0.053, will be paid starting November 27, 2025.
✓ The right to the dividend will be transferred to the buyer until the end of the session on July 7, 2025.
30 / 6 / 2025 Mon
Memphis Pharmaceuticals (MPCI)
The semi-annual disclosure form for the use of capital increase proceeds states:
** 60% of the capital increase proceeds were used to repay shareholders’ creditors (the Holding Company for Pharmaceuticals).*
40% of the capital increase proceeds were used to improve the company’s productivity, meet its raw material needs, and address increasing operating costs.
The total amount raised is EGP 171 million.
28 / 5 / 2025 WED
Rameda RMDA
The dividend distribution for the fiscal year ending 2024 was approved. The dividends will be distributed as follows:
✓ EGP 18 million in cash dividends to employees
✓ EGP 160 million in cash dividends to shareholders, at 10,589 piasters per share
✓ EGP 122.25 million in bonus shares to shareholders, at 0.3236 bonus shares per share
Ibn Sina Pharma ISPH
The company has agreed to replace Ibn Sina Pharma with a new investor in the financial lease contract related to the land, building, and equipment of Al Shorouk Hospital, for EGP 670 million. This is part of the management’s plan to sell non-strategic assets and reduce financial leasing costs.
Expected Results
☑ Debt reduction of approximately EGP 500 million by removing the lease contract from Ibn Sina Pharma’s balance sheet.
☑ Annual expense savings of approximately EGP 150 million (interest and depreciation), the impact of which will be reflected in the income statement starting June 2025.
☑ Achievement of a capital gain of approximately EGP 27 million after deducting liabilities and investments associated with the asset.
21 / 5 / 2025 WED
Prices of 25% of Imported Medicines in Egypt Are Expected to Decrease
Head of the Pharmaceutical Division: The executive order announced by Trump, which reduces medicine prices in the US by 30 to 80%, will contribute to reducing the import bill for 25% of the medicines Egypt imports annually over the coming period. This means that reducing medicine prices in the US will result in a similar reduction for the same items imported to Egypt, in compliance with the price of the country of origin, as a quarter of the medicines Egypt imports annually come from the United States.
Egypt’s import bill from the medical industry amounted to $4.7 billion last year, including medicine imports worth approximately $1.79 billion. Trump’s executive order will reduce Egypt’s medicine import bill from the United States by approximately half a billion dollars annually. (Al Arabiya News)